U lcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract with heterogeneous disease presentation. In nearly 20% of cases, the initial presentation is an acute severe colitis, whereas nearly 50% of patients may never require hospitalization related to their disease. [1] [2] [3] Ulcerative proctitis (UP) is a unique and often mild form of UC, characterized by inflammation limited to the rectum. In most patients with initial diagnosis of proctitis, the disease does not extend to more proximal areas of the large intestine. Specifically, previous studies suggest that only 10% to 30% of patients with UP experience disease extension. [4] [5] [6] [7] [8] [9] It is expected that patients with disease extension are more likely to suffer from UC complications and are at higher risk of requiring treatment escalation. A recent study in pediatric population with new diagnosis of UC demonstrated a 13% cumulative risk of colectomy at 15 years among patients with UP with no difference in the rate of surgery, anti-tumor necrosis factor use, or extension compared with other patients with UC. 6 Nevertheless, data on clinical predictors of disease extension in UP are sparse. In addition, previous studies evaluating risk factors for disease extension in UP were limited by small sample size, single center experience, limited follow-up time, and lack of detailed information on lifestyle factors. 4, 6, 8, 10 Finally, there is a paucity of data on differences in treatment course and disease complications between patients with proctitis with disease extension to those without.
We therefore sought to examine the predictors of extension in patients with initial diagnosis of UP using data from a large health care network. In addition, we explored the differences in treatment patterns between extenders and nonextenders as defined by the need for immunosuppressive medications or biologics and rates of surgery.
METHODS

Study Population
From January 2000 to December 2015, we identified cases of UP using the Research Patient Data Registry (RPDR), which encompasses hospitals within the Partners healthcare system (i. e., Brigham and Women's Hospital, Faulkner Hospital, Massachusetts General Hospital, Newton Wellesley Hospital, and North Shore Medical Center). RPDR is a centralized clinical data registry that gathers clinical information including notes, laboratory results, imaging, procedures, and pathology for both inpatient and ambulatory care. An online query tool allows investigators to explore clinical data through a self-service system, whereas the data request wizards allow the users to ask for more detailed medical record information on the identified patient population.
Cases of UP were identified by searching the RPDR for billing diagnoses of UC OR ulcerative proctitis AND by searching the pathology database among these individuals for key words "chronic active colitis" or "active chronic colitis." Medical records were then reviewed to confirm the initial diagnosis of UP by endoscopy and pathology. Patients who were diagnosed with Crohn's disease, ischemic colitis, or indeterminate colitis during follow-up were excluded.
Clinical Characteristics, Laboratory, and Endoscopic Findings
At the time of diagnosis of proctitis, we collected information on age, race, body mass index (BMI), current medications, smoking status, and family history of inflammatory bowel disease through review of medical records. Similarly, laboratory data including autoimmune markers (e.g., ANA, etc), inflammatory markers (erythrocyte sedimentation rate (ESR) or C-reactive protein), hematocrit, and platelet count at the time of diagnosis were collected. For women, we also collected information on parity and full-term pregnancy over the follow-up time. We used the Simple Clinical Colitis Activity Index to assess clinical activity at the time of diagnosis and Mayo clinic endoscopy score to assess endoscopic activity. When Mayo clinic endoscopy scores were not specifically reported, we (E.W., Y.W. C., S.M.C, and H.K.) reviewed endoscopic images to calculate Mayo clinic score. As cecal patch has previously been reported with distal colitis, we also collected information on the presence of this finding at the initial or subsequent colonoscopies. Finally, information on histology at the time of diagnosis including severity of colitis was also obtained from pathology reports.
Ascertainment of Outcomes
Information on disease extension, defined as endoscopic and histologic evidence of UC beyond the rectum, was obtained through review of medical records. Date of extension was considered to be the date of colonoscopy/sigmoidoscopy at which point extension was identified. Data on UC-related medications including aminosalicylates, steroids, thiopurines (azathioprine and 6-mercaptopurine), methotrexate, cyclosporine, anti-tumor necrosis factor therapy (infliximab, adalimumab, and golimumab), and vedolizumab at any time after diagnosis were also obtained through review of medical records.
Statistical Analysis
Baseline characteristics of participants at the time of proctitis diagnosis were reported in frequency and median for categorical and continuous variables, respectively. Person-time for each participant was calculated from date of diagnosis of proctitis to the date of extension, death from any cause, date of last encounter with the healthcare system, or December 31, 2015, whichever came first. We used Cox proportional hazards modeling, adjusting for covariates to calculate adjusted hazard ratios (aHRs) and 95% confidence interval (CI). We developed a multivariable model using TRIPOD guidelines, incorporating age, sex, previously identified clinical factors associated with extension including appendectomy and smoking, and novel independent factors identified through backward selection modeling using a threshold P value of 0.15. 11 We used the conservative threshold P value of 0.15 based on simulation studies demonstrating that a higher value should be considered in automated selection models, particularly in studies of small sample size. 12, 13 To account for secular trends in patterns of treatment over follow-up time, we stratified all analyses by calendar year. We used Kaplan-Meier curve to demonstrate rate of extension over time and log-rank test to compare treatment course and surgical rates according to disease extension. We used SAS version 9.4 (Cary, NC) for these analyses. All P values were 2-sided, and ,0.05 was considered statistically significant. The study was approved by the Institutional Review Board at the Partners Healthcare.
RESULTS
Through December 2015, we confirmed 169 UP cases with a median follow-up of 4.3 years (range: 3.3-15.1 yr) ( Table 1) . The median age of diagnosis was 40 years (range: 16-91 yr), and most participants were female (55%) and white (82.9%). The median BMI was 24.8 kg/m 2 (range: 17.0-53.1 kg/m 2 ). At the time of diagnosis, nearly 64% of patients had both endoscopic and histologic evidence of moderate to severe colitis and 9.5% had a cecal patch. Through the end of follow-up, 137 (81%) patients had at least 1 follow-up colonoscopy, and 53 patients (31%) developed disease extension with a median time from diagnosis to extension of 2.1 years (range: 0.3-2.9 yr) (Fig. 1) . Among extenders, 36 (67.9%) developed left-sided UC (E2), whereas 17 (32.1%) developed extensive UC (E3).
We sought to identify predictors of disease extension using automated selection models. In multivariable analyses, BMI, endoscopic disease severity, and appendectomy were the only variables that were independently associated with an increased risk of extension (Table 2) . Compared with proctitis cases with BMI less than 25 kg/m 2 , the aHRs of extension were 1.75 (95% CI, 0.95-3.23) and 2.77 (95% CI, 1.07-7.14) among overweight (BMI ¼ 25-29.9 kg/m 2 ) and obese (BMI $ 30 kg/m 2 ) patients, respectively (P trend ¼ 0.03). Similarly, patients with a history of appendectomy or moderate to severe endoscopic activity at the time of diagnosis had over a 2-fold increase in risk of extension (aHR ¼ 2.74, 95% CI, 1.07-7.01 and aHR ¼ 1.96, 95% CI, 1.05-3.67). We also observed an inverse association between current smoking at the time of diagnosis and risk of disease extension compared with nonsmokers, although this also did not reach statistical significance (aHR ¼ 0.23, 95% CI, 0.05-1.13, P ¼ 0.071). Other factors including age of diagnosis, sex, race, inflammatory markers, family history of inflammatory bowel disease, pregnancy, nonsteroidal anti-inflammatory drugs use, and histologic activity were not associated with risk of extension (Supplementary Table 1 , Supplemental Digital Content, http://links.lww.com/IBD/B634).
We considered the possibility that interval censoring of patients without long-term follow-up within the health network may have differentially decreased the follow-up time for patients with mild disease, as they would have been less likely to seek care. Thus, we performed sensitivity analysis extending follow-up to December 2015 for all patients regardless of the number encounters after diagnosis in Partners healthcare network and obtained similar risk estimates compared with our primary analysis. Compared with proctitis cases with BMI less than 25 kg/m 2 , the aHRs of extension were 1.73 (95% CI, 0.94-3.20) and 2.36 (95% CI, 0.95-5.88) among overweight (BMI ¼ 25-29.9 kg/m 2 ) and obese (BMI $ 30 kg/m 2 ) patients, respectively (P trend ¼ 0.04). Similarly, both appendectomy and moderate to severe endoscopic disease activity were associated with an increased risk of extension (aHR ¼ 2.99, 95% CI, 1.17-7.66 and 1.92, 95% CI, 1.02-3.59, respectively). Conversely, smoking at the time of diagnosis was inversely associated with risk of extension (aHR ¼ 0.22, 95% CI, 0.05-1.05).
We next examined whether there were significant differences between treatment patterns of patients with UP and those who developed extension over time. There were no significant differences in use of 5-aminosalicylate or steroids comparing proctitis patients who had disease extension to those without. Specifically, 37 (69.8%) of extenders were prescribed 5-aminosalicylate compared with 97 (83.6%) of nonextenders (P comparison ¼ 0.06). Similarly, 37.7% of extenders and 25% of nonextenders were prescribed steroids (P comparison ¼ 0.10). By contrast, there were significant differences in rates of immunosuppressive and biologic therapy use between the 2 groups (Fig. 2) . Although 18 (34%) extenders were prescribed oral immunosuppressive medications during follow-up, only 3 (2.6%) nonextenders received these medications (P comparison , 0.001). Similarly, 17 (32%) extenders received biologic therapy compared with only 3 (2.6%) nonextenders (P comparison , 0.001) (Fig. 3) . Finally, the rate of colectomy over follow-up also seemed to be higher among extenders, although this comparison did not reach statistical significance (2 [3.8%] versus 1 [0.9%], P ¼ 0.0975) (Fig. 4) . We also considered the possibility that stratifying patients at baseline according to disease extension and future event may have differentially biased our estimates. We, therefore, performed a sensitivity analysis by matching extenders to proctitis cases according to disease duration (61 yr) at the time of diagnosis of extension and compared rates of immunosuppressive and biologic use and obtained similar results (P comparison , 0.001). There was, however, no difference in colectomy rates between the 2 groups (P ¼ 0.29).
DISCUSSION
In a retrospective cohort study, we demonstrated that obesity as measured by BMI at the time of initial diagnosis of proctitis, appendectomy, and disease activity as measured at index endoscopy are associated with an increased risk of extension. In addition, there was a trend toward a decreased risk of extension in current smokers at time of diagnosis, although the risk did not reach statistical significance. Finally, our data suggest that compared with nonextenders, proctitis patients who have extension of their disease beyond the rectum over time are also more likely to be prescribed immunosuppressive and biologic therapy. Our results are supported by several previous findings. In a retrospective cohort study of 98 patients with an average followup of 109 months, Kim et al 7 reported a 27.6% rate of extension. Consistent with our findings, Kim et al also found that disease severity at the time of diagnosis was associated with an increased risk of extension. Similarly, Meucci et al 8 assessed the rate of extension in 272 patients with proctitis with a mean follow-up of 52 months and found an extension rate of 27.1%. They also demonstrated an inverse association between smoking and risk of extension. Interestingly in both studies, BMI at the time of diagnosis was not assessed.
Our data do, however, contrast with findings from other studies. Safroneeva et al 9 did not find an association between BMI and risk of disease extension. However, in their study, rate of disease extension was compared between individuals with BMI greater than 20 to those less than 20. Thus, obesity (defined by BMI .30) could not have been identified as a risk factor for disease extension. In support of this, when using similar categories for BMI in our analysis, we did not find an association between BMI and risk of disease extension. In addition, in a retrospective cohort study from Japan, Anzai et al studied the significance of cecal patch in patients with UC and reported that all 9 proctitis patients with cecal patch had evidence of disease extension through follow-up. However, there was no comparable control group (i.e., patients with proctitis without cecal patch) to determine whether cecal patch is a predictor of extension.
Several studies have examined the relationship between appendectomy and UC. Most studies have demonstrated a potential protective benefit from appendectomy, particularly early in life on risk of development of UC. 10, [14] [15] [16] [17] Although the exact mechanism underlying this previous observation is largely unknown, a number of plausible mechanisms have been proposed. First, animal studies and human data suggest that appendix appears to be a priming site for innate immune cells that play a critical role in development of UC. 18, 19 Second, in mice, appendix/cecal patch plays a critical role in the generation of immunoglobulin-A-producing B cells that are home to the colon but not the small intestine with appendectomy, leading to a delayed accumulation of immunoglobulin-A-producing cells in the large intestine. 20 Third, the appendix may serve as a reservoir for commensal bacteria and, therefore, its removal could lead to more dynamic changes in the colonic microbiota. Despite compelling evidence suggesting the protective role of appendectomy on the development of UC, it remains largely unclear whether appendectomy plays a role in the clinical course of patients with UC or proctitis. 21, 22 In our study, we also demonstrated that appendectomy was associated with an increased risk of extension in patients with UP. This finding is in contrast with previous studies highlighting potential therapeutic benefit of appendectomy in patients with ulcerative proctitis. In a prospective study of 30 patients with the new diagnosis of UP undergoing appendectomy as a treatment, 90% of patients had clinical improvements. 23 Our study is the first to report BMI as an independent predictor of disease extension in patients with UP. Although the precise pathophysiology of UC remains largely unknown, a likely key pathogenic mechanism is the loss of immune tolerance to gut microbiota in genetically susceptible individuals. 24 Nevertheless, it is unclear whether shared biologic pathways drive the pathogenesis of both proctitis and UC, particularly because a large proportion of patients with proctitis have mild and limited disease. Our finding that BMI at the time of diagnosis is associated with an risk of extension may therefore have biologic implications. First, obesity has been previously linked to significant alterations in the structure of gut microbiota. In obese mice, there is a 50% reduction in abundance of Bacteroidetes with a proportional increase in Firmicutes. 25, 26 Similar findings have been reported in obese human subjects. 27 Second, obesity as measured by BMI has been linked to elevated levels of proinflammatory markers such as tumor necrosis factor-alpha and C-reactive protein. 28, 29 Third, obese individuals have been shown to have higher levels of inflammation in the gastrointestinal tract as measured by stool calprotectin. 30 Therefore, it is possible that obesity, through its effect on the gut microbiota and immune function, may drive the evolution of proctitis into UC.
Our study has several strengths. First, we confirmed all cases of proctitis by medical records reviews using standardized criteria, representing a significant advantage over previous studies that rely on self-report or clinic/hospital discharged codes, which may not accurately reflect true diagnoses. Second, we collected detailed information on other important lifestyle factors, medications, as well as endoscopic, laboratory, and histologic findings in nearly all of our cases, and were therefore able to identify novel risk factors for disease extension. Finally, our relatively long follow-up allowed for a more precise estimate of the risk over time.
Our study has several limitations. First, although our samples size was similar, if not larger than most of the previous studies, we may have had limited power to detect more modest differences or associations. Second, we did not have complete data on the time period before diagnosis of disease and therefore could not fully account for use of other medications that may have contributed to disease extension. Third, data on endoscopic activity was collected from review of procedural reports and images, which may introduce biases related to interobserver differences. However, the correlation between endoscopic scoring across the study reviewers was excellent (r ¼ 0.92). Fourth, as not all patients in the study had follow-up colonoscopy, we cannot definitively exclude the possibility of outcome misclassification. Nevertheless, individuals with disease extension are more likely to be symptomatic and therefore receive endoscopic evaluation. Finally, our study is observational and therefore we cannot rule out the possibility of residual confounding. However, we collected data on all factors that have previously been associated with progression of proctitis/UC and considered them in all analyses.
In a retrospective cohort study, we show that appendectomy, BMI, and endoscopic severity at the time of diagnosis of proctitis are associated with an increased risk of extension. In addition, our data suggest that extenders are more likely to require immunosuppressive or biologic therapy over time. If validated, these results could guide the development of targeted therapeutic algorithms for those patients who may be at the highest risk of disease progression.
